Abstract:Abstract Funding Acknowledgements Type of funding sources: Public grant(s) – National budget only. Main funding source(s): West Midlands Academic Health Science Network. Background After an acute coronary syndrome (ACS), there is a persistent ~10% risk of recurrent ACS or death in the following year and a further ~10% risk between years 1-4. Several more recent guideline-recommended treatments that could reduce this risk (Knuuti et al 2019) and may be under-utilised. Some of these, such as long-term dual antithrombotic therapy, are recommended for patients with high cardiovascular risk. Others benefit patients with type 2 diabetes mellitus (SGLT2 inhibitors and GLP1 agonists), hypercholesterolaemia (ezetimibe and PCSK9 inhibitors) or heart failure (mineralocorticoid antagonists and sacubitril/valsartan in addition to ACE inhibitors and beta blockers). Methods We were recently awarded funding from the West Midlands Academic Health Science Network (UK) to introduce a new advanced secondary prevention clinic that focusses on more recent medications with recommendations from National Institute for Health and Care Excellence (NICE NG185 and relevant technology appraisals) and the ESC. In an audit we compared use of medications in the prevention clinic (n=57) with similar patients with prior ACS seen in standard cardiology clinics (n=109) between 2020-21 in our National Health Service (NHS) Trust (Fig 1.). Results Assessment of eligibility for medications was complex, but showed similar eligibility in prevention clinics and standard clinics. Patients were uniformly eligible for statins and ACE inhibitors, whereas NICE and ESC guidelines in some cases disagreed on eligibility of individual patients for dual antithrombotic therapy, beta blockers and ezetimibe. Use of treatments with definitive guideline recommendations from both NICE and ESC was determined for each patient (Fig 1). There was significantly higher adherence to these definitive recommendations in prevention vs. standard clinics (Fig 1), including SGLT2 inhibitors/GLP1 agonists (17/18 [94%] vs. 5/29 [17%]; P<0.001), PCSK9 inhibitors (3/3 [100%] vs. 0/6 [0%]; P=0.01), ezetimibe (23/25 [92%] vs. 11/48 [23%]; P<0.001], long-term dual antithrombotic therapy (22/23 [96%] vs. 3/31 [10%]; P<0.001]) and statins at a recommended dose (52/53 [98%] vs. 82/101 [81%]; P<0.001. Peer consultation identified several barriers to use of medications: complexity of treatment algorithms (which often differ between guidelines); need for personalisation (the audit identified >50 unique combinations of recommended treatments for individual patients); complex risk assessments; and time constraints in gathering data to assess eligibility the medications (often takes >5 min), exacerbated by high patient volume. Conclusions Several guideline-recommended medications with established cardiovascular benefit were under-utilised in standard clinics after ACS. Specialist preventative cardiology clinics can optimise utilisation of these medications, which has the potential to reduce the risk of further major adverse cardiovascular events. Innovative solutions are needed to scale this further.

Targeted case finding improves treatment of patients at high risk for CVD, study finds

Targeted case finding beats universal CVD screening, UK study finds

Treating to protect: current cardiovascular treatment approaches and remaining needs

Case management for blood pressure and lipid level control after minor stroke: PREVENTION randomized controlled trial

Subclinical atherosclerosis, cardiovascular health, and disease risk: is there a case for the Cardiovascular Health Index in the primary prevention population?

Improving cardiovascular prevention in general practice: Results of a comprehensive personalized strategy in subjects at high risk

Age and sex specific thresholds for risk stratification of cardiovascular disease and clinical decision making: prospective open cohort study

Using coronary artery calcium to guide cardiovascular risk reduction: insights from the CAUGHT-CAD trial

A phase II study of paclitaxel and capecitabine combination chemotherapy in patients with advanced gastric cancer as a first-line therapy.

Machine-learning-based high-benefit approach versus conventional high-risk approach in blood pressure management

Association between glutathione S-transferase M1 and T1 polymorphisms and increased risk for bladder cancer in Korean smokers.

Strategies for Primary Prevention of Coronary Heart Disease Based on Risk Stratification by the ACC/AHA Lipid Guidelines, ATP III Guidelines, Coronary Calcium Scoring, and C-Reactive Protein, and a Global Treat-All Strategy: A Comparative--Effectiveness Modeling Study

Improved adherence to guideline-recommended treatments in a specialist preventative pharmacology clinic compared to standard cardiology clinics after an acute coronary syndrome

[Targeting dyslipidaemia in primary prevention of cardiovascular disease]

Immediate Versus 5-Year Risk-Guided Initiation of Treatment for Primary Prevention of Cardiovascular Disease for Australians Aged 40 Years: A Health Economic Analysis

Cardiovascular disease — risk assessment and reduction: NICE 2023 update for GPs

Greater use of antihypertensive medications explains lower blood pressures and better control in statin-treated than statin-eligible untreated adults

Treatment Gap in Primary Prevention Patients Presenting With Acute Coronary Syndrome

Modeling the Impact of Biomarker-Guided Versus ASCVD Risk–Guided Drug Treatment in US Adults With Stage 1 Hypertension: The National Health and Nutrition Examination Survey, 1999 to 2004

Assessing Cardiovascular Disease Risk and Responses to Preventive Therapies in Clinical Practice

Outcomes of an integrated community-based nurse-led cardiovascular disease prevention programme